
BPMX
Healthcare · Biotechnology · $776,821 market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Apr 30, 2020
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Jun 12, 2020 | Time not confirmed | -0.84 | -1.34 | -59.5% |
| Mar 14, 2019 | Time not confirmed | -0.50 | -0.25 | +50.0% |
| Dec 6, 2018 | Time not confirmed | -0.50 | -0.50 | 0.0% |
| Aug 30, 2018 | Time not confirmed | -0.50 | -0.50 | 0.0% |
| Jun 14, 2018 | Time not confirmed | -0.04 | -0.03 | +25.0% |
BioPharmX Corporation, a specialty pharmaceutical company, develops products for the treatment of dermatologic conditions using its proprietary HyantX topical delivery system. Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase IIb clinical trials for the treatment of inflammatory lesions of acne; and BPX04, a topical antibiotic, which is in Phase IIb study for the…